What Does the Science Say About Reglan and Tardive Dyskinesia?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

Can I sue for tardive dyskinesia caused by Reglan in California

Yes, if you developed tardive dyskinesia from Reglan (metoclopramide), you may have a legal claim. The FDA requires a black box warning about this risk, especially with long-term use. A California attorney can evaluate your case for potential negligence or failure to warn. Consult a qualified legal professional for advice specific to your situation.

From General Health Awareness to Targeted Risk Education

If you or a loved one has taken Reglan and noticed unusual, involuntary movements, you may be concerned about tardive dyskinesia. This condition has been linked to long-term or high-dose use of metoclopramide, the active ingredient in Reglan. The medical community has long recognized the importance of balancing therapeutic benefits with potential risks, and this page provides a clear overview of what current reports say about Reglan and tardive dyskinesia, including symptoms, risk factors, and monitoring recommendations.

Understanding Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent commonly prescribed for gastrointestinal conditions such as diabetic gastroparesis and gastroesophageal reflux. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. This section examines the clinical presentation of TD, the pharmacology of Reglan, the mechanistic link between the drug and TD, and risk considerations for affected patients, including settlement-related factors. Tardive dyskinesia is characterized by involuntary, repetitive movements, often involving the face, tongue, trunk, or extremities. The condition can be disfiguring and may persist even after the offending drug is discontinued. According to the FDA-approved labeling, metoclopramide, including Reglan, can cause TD, a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Diagnosis typically involves clinical evaluation of abnormal movements, with consideration of risk factors such as advanced age, female sex, and prolonged exposure to dopamine receptor blocking agents.

Pharmacology and Mechanism of Reglan-Induced Tardive Dyskinesia

Reglan's pharmacology centers on its action as a dopamine D2-receptor antagonist. This mechanism is effective for treating nausea, vomiting, and gastroparesis, but it also underlies the development of extrapyramidal side effects, including TD. As described in a case report, metoclopramide is a dopamine D2-receptor blocking agent commonly used to treat nausea, vomiting, and gastroparesis, and due to its mechanism of action, these drugs can lead to extrapyramidal side effects such as tardive dyskinesia (https://pubmed.ncbi.nlm.nih.gov/34712535/). The risk of TD increases with duration of treatment and total cumulative dosage, as emphasized in the boxed warning: the risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling further advises using Reglan for the shortest duration of treatment and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves chronic blockade of dopamine D2 receptors in the striatum, leading to upregulation of dopamine receptors and subsequent hypersensitivity. This dysregulation results in the involuntary movements characteristic of TD. While TD was initially associated with typical antipsychotics, the incidence is likely similar with atypical antipsychotics and antiemetics such as metoclopramide (https://pubmed.ncbi.nlm.nih.gov/29433808/). Increased prescribing of these agents, along with low rates of remission, has contributed to a rising prevalence of TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). Notably, TD can occur even after a single dose, as reported in a case of a postoperative gynecological patient who developed dyskinetic movements after intraoperative administration of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). This underscores the importance of vigilance, even with short-term use.

Risk Considerations and Settlement Factors for California Patients

Risk considerations for patients include the adequacy of warnings regarding Reglan and TD. The FDA requires a boxed warning on Reglan labeling, which states that metoclopramide can cause TD, a potentially irreversible serious movement disorder, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning also notes that Reglan is contraindicated in patients with a history of TD and that treatment should be discontinued immediately if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the labeling advises avoiding total treatment duration longer than 12 weeks, and if longer-term use is unavoidable, routinely monitoring for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, some patients may not receive adequate information about the risk, particularly if prescribed for off-label uses or for extended periods. Settlement-related considerations for affected patients in California involve legal claims based on inadequate warnings or failure to monitor. The timeline between exposure and documented harm is critical. TD may develop after months or years of treatment, but cases have been reported after a single dose (https://pubmed.ncbi.nlm.nih.gov/34712535/). Patients who develop TD after Reglan use may seek compensation for medical expenses, pain and suffering, and lost wages. The boxed warning and labeling provide a basis for arguing that manufacturers had a duty to warn about the risk of TD, and that failure to do so could constitute negligence. However, each case depends on individual circumstances, including duration of use, presence of risk factors, and whether the patient was monitored appropriately.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is tardive dyskinesia and how is it related to Reglan?

Tardive dyskinesia (TD) is a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. Reglan (metoclopramide) is a dopamine D2-receptor antagonist that can cause TD by chronically blocking dopamine receptors in the brain, leading to receptor hypersensitivity. The FDA requires a boxed warning on Reglan labeling about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What are the risk factors for developing tardive dyskinesia from Reglan?

Risk factors include advanced age, female sex, prolonged treatment duration, and higher cumulative dosage. However, TD can occur even after short-term use or a single dose, as reported in a case study (https://pubmed.ncbi.nlm.nih.gov/34712535/). The FDA advises using Reglan for the shortest duration necessary and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Can I file a lawsuit if I developed tardive dyskinesia after taking Reglan?

Yes, affected patients in California may pursue legal claims based on inadequate warnings or failure to monitor. The FDA boxed warning and labeling establish a duty for manufacturers to warn about TD risk. Each case depends on individual factors such as duration of use, risk factors, and whether monitoring occurred. Consulting a qualified attorney is recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.